Skip to main
ALXO
ALXO logo

ALXO Stock Forecast & Price Target

ALXO Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

ALX Oncology Holdings Inc. is making significant strides in the clinical-stage immuno-oncology sector with its innovative pipeline featuring the CD47 blocker, evorpacept, which is currently undergoing phase 1 and 2 trials. The company's expansion into new products, such as the EGFR-targeting ADC ALX2004, indicates a commitment to enhancing treatment safety and efficacy, particularly through improved linker-payload stability. Promising early trial results, including a median progression-free survival (mPFS) of approximately 9.5 months for patients treated with evorpacept in combination with other therapies, underscore a potentially positive trajectory for both ALX's product candidates and its overall market position.

Bears say

ALX Oncology Holdings Inc. has revised its financial model, indicating diminished confidence in its gastric cancer program and awaiting crucial proof of concept data for additional tumor types. The company lowered its peak market penetration rate estimate for Head and Neck cancer due to increased competition, reflecting a more cautious outlook on its revenue potential. Furthermore, the absence of any reported revenues in the fourth quarter of 2024, alongside a significant net loss per share, coupled with high risks associated with FDA approval pathways, contribute to the prevailing negative sentiment surrounding the stock.

ALXO has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ALX Onconology Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ALX Onconology Holdings Inc (ALXO) Forecast

Analysts have given ALXO a Buy based on their latest research and market trends.

According to 7 analysts, ALXO has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ALX Onconology Holdings Inc (ALXO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.